Images List Premium Download Classic

C Syndrome

C Syndrome-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical composition comprising amorphous lenalidomide
Synthon B.v.
December 28, 2017 - N°20170368197

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted β-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.
Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
December 28, 2017 - N°20170368133

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
Pharmaceutical composition comprising amorphous lenalidomide
Synthon B.v.
December 28, 2017 - N°20170368048

The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Activin-actrii antagonists and uses for treating anemia
Acceleron Pharma Inc.
December 21, 2017 - N°20170360887

Provided herein are methods for the treatment in a subject of anemia, anemia requiring rbc transfusion, low or intermediate-1-risk myelodysplastic syndromes (mds), and/or non-proliferative chronic myelomonocytic leukemia (cmml) in any mammals wherein the methods comprise administration of activin-actrii signaling inhibitors to a subject in need of the treatment.
Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
December 14, 2017 - N°20170354640

The disclosure provides thiol-containing alkyl fatty acid and vitamin d compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, metabolic syndrome and diabetes. Also provided are methods of treatment comprising the daily administration of the disclosed thiolcontaining alkyl fatty acid formulations ...
Hydroxyl compounds and compositions for cholesterol management and related uses
Esperion Therapeutics, Inc.
December 07, 2017 - N°20170349516

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination ...
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)...
Celgene Corporation
December 07, 2017 - N°20170348298

Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
Method of treating liver fibrosis
Chemocentryx, Inc.
December 07, 2017 - N°20170348293

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms).
Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient
Industry Foundation Of Chonnam National University
November 30, 2017 - N°20170340660

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions ...
Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
Lixte Biotechnology, Inc.
November 30, 2017 - N°20170340628

Disclosed are methods for treating a myelodysplastic syndrome (mds) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2a (pp2a) inhibitor.
Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
November 30, 2017 - N°20170340584

The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic ...
Compositions and methods for treating cancers
Aptose Biosciences Inc.
November 23, 2017 - N°20170335400

The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the cdx2-klf4 signaling pathway to treat myelodysplastic syndromes (mds), acute myelogenous leukemia (aml), acute lymphocytic leukemia (all), adult t-cell leukaemia (atll), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or ...
Anti-acth antibodies and use thereof
Alder Biopharmaceuticals, Inc.
November 23, 2017 - N°20170334987

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-acth antibodies and binding fragments thereof conjugated ...
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method and apparatus for noninvasive inhibition of deep vein thrombosis
Stimmed Llc
November 23, 2017 - N°20170333695

System, device and method for providing neuromuscular electrical stimulation (nmes) to muscles of foot. The device includes an electrical signal generator for producing a wave pattern of variable frequency, duration, intensity, ramp time and on-off cycle. The device further includes surface electrodes for being positioned over the foot muscles or around ankles and attached to the signal generator. The device ...
Ovarian neuromodulation and associated systems and methods
Medtronic Ardian Luxembourg S.a.r.l.
November 23, 2017 - N°20170333126

Methods for treating polycystic ovary syndrome with therapeutic ovarian neuromodulation and associated systems and methods are disclosed herein. Polycystic ovary syndrome can be associated, for example, with a condition including at least one of oligo/amenorrhea, infertility, hirsutism, obesity, metabolic syndrome, insulin resistance, and increased cardiovascular risk profile. One aspect of the present technology is directed to methods that at ...
Omefibrates for treating dyslipidemia and cardiovascular disease
Jiva Pharma, Inc.
November 16, 2017 - N°20170327455

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).
Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome
Duke University
November 16, 2017 - N°20170326199

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2.
Metap2 inhibitors and methods of treating obesity
Syndevrx, Inc.
November 16, 2017 - N°20170326135

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or ...
Methods of treating myelodysplastic syndrome with farnesyltransferase inhibitors
Kura Oncology, Inc.
November 16, 2017 - N°20170326133

The present invention relates to the field of molecular biology, cell biology, and cancer biology. Specifically, the present invention relates to methods of treating myelodysplastic syndrome (“mds”) with a farnesyltransferase inhibitor (fti) that include determining whether the subject is likely to be responsive to the fti treatment based on the th1/th2 balance and additional characteristics.
Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
The U.s. Government As Represented By The Departme Nt Of Veterans Affairs Office Of General Counsel
November 09, 2017 - N°20170321277

Described herein are assays, methods, and devices for diagnosing/prognosing diabetes, metabolic syndrome, pre-diabetic state and/or the early-onset of diabetes in a subject. The assays, methods, and devices described herein can be configured to detect one or more long-coding rnas in a sample from a subject.
A dietary fibre composition
Inqpharm Group Sdn Bhd
November 09, 2017 - N°20170319616

The invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity.
Loading